Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Aerosol Cyclosporine for Prevention of Lung Rejection
- Conditions
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
- First Posted Date
- 2005-12-08
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT00263328
- Locations
- 🇺🇸
Annette C & Harold C Simmons Transplant Institute, Dallas, Texas, United States
🇺🇸Transplant Research Institute, Los Angeles, California, United States
🇺🇸Balboa Institute of Transplantation, San Diego, California, United States
Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 35
- Registration Number
- NCT00262886
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
Study Comparing Two Immunosuppressive Regimens in De Novo Renal Allograft Recipients
- Conditions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2006-05-19
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00261820
Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus
- Conditions
- Interventions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 361
- Registration Number
- NCT00260208
- Locations
- 🇨🇭
Novartis Investigational Site, Zurich, Switzerland
🇺🇸Novartis Investigative Site, East Hanover, New Jersey, United States
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2010-03-17
- Target Recruit Count
- 60
- Registration Number
- NCT00255710
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2017-01-02
- Target Recruit Count
- 35
- Registration Number
- NCT00240994
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital, Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital, Boston, Boston, Massachusetts, United States
Polymorphism of the Cytochrome P450-system in Renal Transplants
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University Hospital Schleswig-Holstein
- Target Recruit Count
- 200
- Registration Number
- NCT00223054
- Locations
- 🇩🇪
University of Schleswig-Holstein, Campus Kiel, Department of Nephrology, Kiel, Germany
Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis
- Conditions
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Comparison of the Two Immunosuppressive Regimens Based on Tacrolimus and Cyclosporine Following Kidney Transplantation
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-19
- Lead Sponsor
- Uniwersytet Mikolaja Kopernika w Toruniu
- Target Recruit Count
- 300
- Registration Number
- NCT00204191
- Locations
- 🇵🇱
Klinika Transplantologii, Szpital Uniwersytecki, ul. M. Sklodowskiej-Curie 9, Bydgoszcz, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.